CurrentBlue Cross Blue Shield - MassachusettsPolicy 200

Transanal endoscopic microsurgery (TEM) for rectal tumors

Clinical coverage policy for TEM (transanal endoscopic microsurgery) for commercial and Medicare members of Blue Cross Blue Shield - Massachusetts, specifying when TEM is considered medically necessary versus investigational and prior authorization requirements.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyTransanal endoscopic microsurgery (TEM) for rectal tumors

Policy CodePolicy 200

Change TypeAnnual reviewclarification

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for inpatient TEM and document tumor location, clinical nodal status, biopsy grade, and tumor circumference when submitting claims or authorization requests.

SourceLink

POLICY UPDATE CHANGES

PA information section clarified to include Medicare.

Annual policy review with updates to description, summary, and references.

1CPT code listed for TEM

4Clinical criteria items required for TEM to be medically necessary for T1 rectal adenocarcinoma

investigationalStatus for tumors not meeting specified criteria

When TEM Is Considered Medically Necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medically necessary — Rectal adenomas

Transanal endoscopic microsurgery for treatment of rectal adenomas, including recurrent adenomas that cannot be removed using other means of local excision, may be considered MEDICALLY NECESSARY when ALL of the following are met:

ALL of the following

Lesion is a rectal adenoma (including recurrent adenomas not removable by other local excision methods)
Lesion cannot be removed using other means of local excision (e.g., unable to be removed endoscopically or by direct local excision)

Medically necessary — Clinical stage T1 rectal adenocarcinoma

Transanal endoscopic microsurgery for treatment of clinical stage T1 rectal adenocarcinomas that cannot be removed using other means of local excision may be considered MEDICALLY NECESSARY when ALL of the following criteria are met:

ALL of the following

Tumor located in the middle or upper part of the rectum
Policy explicitly requires middle or upper rectal location
No lymphadenopathy present
Based on clinical staging
Tumor biopsy shows well or moderately differentiated histology (Grade 1 or Grade 2)
Tumor involves less than one-third of the circumference of the rectum< 1/3 circumference
Tumor cannot be removed by other means of local excision
Criterion mirrors adenoma requirement

Not covered / Investigational

Transanal endoscopic microsurgery for rectal tumors that do not meet the above criteria is considered INVESTIGATIONAL.

ANY of the following

Tumors not meeting the adenoma or T1 adenocarcinoma criteria above (e.g., larger circumference, higher grade, presence of lymphadenopathy, unfavorable location)

Authorization and Documentation Requirements

Prior Authorization

Precertification / Preauthorization required for inpatient procedures

Precertification/preauthorization is required for services described in this policy when the procedure is performed inpatient; obtain authorization per product rules before inpatient TEM.

Affected code: 0184T

Prior Authorization

Prior authorization may be required for outpatient procedures for some products

Prior authorization requirements for outpatient TEM vary by product; providers must check the member’s product-specific prior authorization rules before scheduling outpatient procedures.

Affected code: 0184T

Documentation Required

Documentation of clinical staging and pathology required

Document clinical staging and pathology findings to support medical necessity when submitting claims or prior authorization requests for TEM.

Tumor location (middle or upper rectum)
Clinical nodal status — absence of lymphadenopathy
Biopsy grade — well or moderately differentiated (G1 or G2)
Tumor circumference involvement (less than 1/3 of the rectal circumference)
Affected code: 0184T

Clinical Context and Rationale

Transanal endoscopic microsurgery (TEM) is a minimally invasive, localized excision technique that uses a specialized magnifying rectoscope and instrumentation to extend the reach of local excision beyond direct visualization of the rectum. It is used to remove lesions that cannot be accessed or fully resected with standard endoscopic or direct local excision techniques, permitting organ-sparing management under general or regional anesthesia. CPT code 0184T describes excision of a rectal tumor via the transanal endoscopic microsurgical approach (TEMS).

Common indications include removal of large benign rectal polyps (including recurrent adenomas not removable by other local excision methods) and select early-stage malignant lesions, most notably clinically staged T1 rectal adenocarcinomas confined to the submucosa. TEM can avoid the morbidity associated with radical rectal surgery (for example, risks of fecal incontinence and potential need for permanent colostomy) and may be an informed alternative for appropriately selected patients.

TEM has important limitations that drive the policy criteria. Local excision does not permit lymph node sampling, and presurgical clinical staging can miss regional nodal spread (reported up to about 15% in some series). Reported outcomes include fewer postoperative complications but higher local recurrence rates and, in some analyses, potentially higher metastatic disease or worse long-term outcomes compared with radical resection. Because of these limitations, policy criteria specify tumor characteristics and documentation required to consider TEM medically necessary (eg, lesion type, location, absence of lymphadenopathy, biopsy grade, and circumference involvement).

The coverage approach reflects this balance: TEM is considered medically necessary for rectal adenomas that cannot be removed by other means and for carefully selected clinical T1 adenocarcinomas meeting all specified criteria (middle or upper rectal location, no lymphadenopathy, well/moderately differentiated histology, and less than 1/3 of rectal circumference). Tumors that do not meet these criteria are considered investigational. This rationale aims to preserve organ function while limiting use of TEM to patients with the lowest likelihood of occult nodal disease or adverse pathologic features.

Policy Changes

2025-01revisedLatest

Annual policy review: description, summary, and references updated; policy statements unchanged.

2024-01revised

Annual policy review: description, summary, and references updated; policy statements unchanged.

2023-01clarified

PA information section clarified to include Medicare; annual policy review with updates to description, summary, and references; policy statements unchanged.

2021-01revised

Annual policy review: description, summary, and references updated; policy statements unchanged.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyTransanal endoscopic microsurgery (TEM) for rectal tumors

Policy CodePolicy 200

Change TypeAnnual reviewclarification

Effective Date

Next Review Date

SourceLink

On This Page

D01.2	Carcinoma in situ of rectum
D12.8	Benign neoplasm of rectum (other specified)

OpenPayer

Transanal endoscopic microsurgery (TEM) for rectal tumors

When TEM Is Considered Medically Necessary

Relevant Procedure and Diagnosis Codes

Authorization and Documentation Requirements

Clinical Context and Rationale

Key Terms

Numeric / Clinical Thresholds

Policy Changes